Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial

Journal:

The Lancet

Published:

2025-11-09

DOI:

10.1016/s0140-6736(25)02014-8

Affiliations:

12

Authors:

107

Go to article

Institutions	Authors	Share
AstraZeneca Sweden, Sweden	4.181818	0.30
AstraZeneca Gaithersburg, MD, United States of America (USA)	2.181818	0.16
University Medical Center Groningen (UMCG), RUG, Netherlands	1.090909	0.08
AstraZeneca United States, United States of America (USA)	1.090909	0.08
Renal Associates P.A., United States of America (USA)	1.090909	0.08
Indago Research, United States of America (USA)	1.090909	0.08
AstraZeneca Poland, Poland	1.090909	0.08
Clinical Research Solutions Inc, Canada	1.090909	0.08
University of Glasgow, United Kingdom (UK)	1.090909	0.08

Interested in Clinical Sciences?